Georgia Capital Q1 2026 slides: portfolio EBITDA surges 27% y-o-y

Georgia Capital reported strong Q1 2026 operating performance, with aggregated private portfolio revenue up 13.7% year over year and EBITDA up 26.9%, while NAV per share rose 9.1% to GEL 168.92 by April 27. The company continues to execute on its GEL 700 million capital return program, having deployed about GEL 550 million, and maintains a low NCC ratio of 3.9% with net cash of roughly US$35 million. Retail pharmacy was a standout, with revenue up 8.3%, EBITDA up 20.5%, and gross margin expanding 170 bps to 34.0%.

Analysis

The market is underappreciating the asymmetry in holding-company buybacks when the underlying asset base is compounding faster than the discount is closing. If the discount persists in the mid-teens while portfolio cash generation stays strong, repurchases become mechanically more accretive each quarter because capital is being retired below a still-rising NAV; that makes the equity effectively a levered call on continued execution rather than a simple conglomerate holding. The key second-order effect is that management’s stated flexibility to extinguish debt and then recycle capital into more repurchases creates a self-reinforcing loop: lower leverage, lower perceived risk, tighter discount, higher buyback accretion.

The bigger winner is not the obvious retail pharmacy asset alone but the combination of consumer defensiveness and balance-sheet optionality across the platform. In an inflationary or geopolitical stress regime, businesses with pricing power and short working-capital cycles tend to keep compounding while cyclical public names de-rate; that widens the relative valuation gap versus local listed peers and supports continued capital recycling into the cheapest look-through exposure. The China/Turkey/EM supply-chain angle matters less than domestic demand durability here; the real risk is not operational breakage but whether the market rerates the holding company fast enough to make buybacks less compelling than holding cash.

The contrarian view is that this is no longer a deep-discount recovery story; it is becoming a quality compounder story with less room for multiple expansion, so absolute upside likely depends on persistent execution rather than mean reversion. The main reversal catalyst would be a downturn in bank/financial-market-linked NAV contributors or a deterioration in Georgian macro that pressures confidence in the discount narrative. Time horizon matters: the next 1-3 months can still be driven by capital return optics and index-related flows, but the 6-12 month outcome will be determined by whether EBITDA growth translates into sustained free cash flow and whether management keeps over-delivering on capital returns.

Key Decisions for Investors

• Long CGEO on pullbacks over the next 2-4 weeks; target a re-rating toward low-teens NAV discount if buyback pace remains intact, with downside protected by ongoing accretion from repurchases and portfolio cash generation.
• Pair trade: long CGEO / short a basket of local or EM financial holdings with weaker buyback discipline over 3-6 months; thesis is that capital return plus private-asset compounding should outperform pure market-beta exposure.
• Sell downside via CGEO put spreads 3-6 months out if liquidity is sufficient; volatility should be cushioned by the company’s stated return program, while theta works in favor if the discount does not widen materially.
• If you already own the name, trim only on sharp spikes rather than strength overall; add only if the discount widens back above current levels, since buyback accretion is highest when the stock is cheap relative to NAV.
• Monitor for a catalyst break: any sign that dividend inflows or holding-company cash generation misses guidance should be treated as a de-risking trigger, because the stock’s support case is built on capital return continuity rather than multiple expansion alone.